2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5223 Analysis of mutational exclusivity, co-occurrence, and prognostic gene pairs across myeloid malignancies after adjustment for diagnosis and mutational burden

Aline Nishimoto, MD, Frederico Honorato Honorato Jr, MD2, Luiz Ferreira Cortes3, Luana Nobrega, MD4, André Dias Américo, MD5, Alexandre Eiji Eiji Kayano, MD6, Amanda Ennes Inacio Dias dos Santos, MD7, Tarcila Santos Datoguia, MD8, Jade Zezzi Martins do Nascimento, MD9, Kira Bucci, MD10, Juliana Dall Agnol Rocha, MD11, Carolina Perrone Marques Ferreira, MD12, Paloma Resende, MD13, Nelson Hamerschlak Sr, MD PhD14, Elvira Deolinda R.P. Velloso Sr, Dr15, Paulo Vidal Campregher, MD, PhD16, Fabio Pires S Santos, MD, PhD17
1 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
2 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
3 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil, Genesis Genomics, São Paulo, SP, Brazil, São Paulo, São Paulo, Brazil, Laboratório Clínico, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
4 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
5 BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
6 Hospital das Clínicas da FMUSP, São Paulo, São Paulo, São Paulo, Brazil, Laboratório Clínico, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
7 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
8 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
9 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
10 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
11 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
12 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
13 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
14 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
15 Hospital das Clínicas da FMUSP, São Paulo, São Paulo, São Paulo, Brazil, Laboratório Clínico, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil
16 Genesis Genomics, São Paulo, SP, Brazil, São Paulo, São Paulo, Brazil
17 Centro de Oncologia e Hematologia, Einstein Hospital Israelita, São Paulo, SP, Brazil, São Paulo, Brazil

Background: Myeloid malignancies share a recurrent set of mutated genes but differ in phenotype and outcome. Genomic studies have identified patterns of mutual exclusivity, which may reflect pathway or functional redundancy and patterns of co-occurrence, which may indicate biological cooperation. These analyses are often limited by cohort size and confounded by diagnosis, sequencing-panel coverage, and mutational burden. We mapped both patterns in a large pan-myeloid dataset while accounting for these factors and evaluated whether specific combinations provided prognostic information beyond the individual genes.

Methods: We analyzed 12 public sequencing datasets comprising 13,398 patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), or myelodysplastic/myeloproliferative neoplasms (MDS/MPN). Gene pairs were tested only in datasets covering both genes. Mutual exclusivity and co-occurrence were assessed using DISCOVER, which accounts for patient-level mutational burden. We performed a pan-myeloid analysis stratified by diagnosis and a cohort-level DerSimonian-Laird meta-analysis, with heterogeneity quantified by I². Effect size was defined as log2(observed/expected [O/E]), and strong effects as an absolute log2(O/E) ≥1.5. Diagnosis-specific effects were tested using logistic regression with a gene pair by diagnosis interaction, adjusted for age, sex, and mutational burden. A mixed-effects model with study as a random effect was used as a sensitivity analysis. Higher-order modules were assessed using log-linear k-way interaction models. Overall survival was analyzed using Cox regression stratified by study and adjusted for age, sex, diagnosis, mutational burden, and the individual genes. Multiple testing was controlled at FDR <0.05.

Results: Among 1,035 testable pairs, 392 were mutually exclusive at FDR <0.05; 225 had log2(O/E) <−1, including 96 with log2(O/E) <−1.5. The strongest exclusion involved NPM1 and TP53 (−3.89). In addition to established exclusions involving TET2 and IDH1/IDH2 and among spliceosome genes, previously unreported associations included CBL/KDM6A (−2.75), RAD21/U2AF1 (−2.59), STAG2/TP53 (−2.30), CEBPA/PHF6 (−2.23), and exclusion of WT1 from TP53 and spliceosome mutations. Sixteen strongly exclusive pairs showed diagnosis dependence. CALR/JAK2 was strongly exclusive only in MPN (−4.80; I²=97%). Other diagnosis-dependent pairs included CEBPA/U2AF1 in AML (−2.71) and DNMT3A/PHF6 in MDS and MDS/MPN (−2.39 and −2.03). Fourteen higher-order exclusivity modules were identified, including NPM1/RUNX1/TP53 and FLT3/IDH2/NRAS/KIT/TP53 in AML.

Co-occurrence was less frequent, with 33 significant pairs, generally with smaller effect sizes, including DNMT3A/NPM1 (+0.63). The strongest associations were ETV6/SETBP1 (+1.41), CEBPA/GATA2 (+1.19), BCOR/RUNX1 (+1.07), and NF1/SH2B3 (+1.05). Four co-occurrence modules were significant: DNMT3A/NPM1/FLT3 (+1.12), BCOR/RUNX1/STAG2 (+2.24), and ASXL1/RUNX1/STAG2 with either EZH2 (+2.86) or SRSF2 (+2.76). None showed significant higher-order interaction beyond its constituent pairs.

Among 7,759 patients with follow-up, co-mutation in at least one pair classified as mutually exclusive was associated with shorter survival (HR 1.26; P=1.4×10−11), but not after adjustment for mutational burden (HR 1.05; P=0.18). Six co-occurring pairs remained associated with survival after adjustment for the individual genes and clinical covariates. DNMT3A/FLT3 (HR 1.39), DNMT3A/NPM1 (HR 1.24), ASXL1/STAG2 (HR 1.44), and SRSF2/STAG2 (HR 1.45) were associated with shorter survival, whereas CEBPA/GATA2 (HR 0.51) and BCOR/RUNX1 (HR 0.68) were associated with longer survival.

Conclusions: In this pan-myeloid analysis of pairwise combinations of recurrently mutated genes, mutual exclusivity was substantially more frequent and had larger effect sizes than co-occurrence across myeloid malignancies. Several exclusions were diagnosis-specific, indicating that disease context modifies pairwise relationships. The tested higher-order co-occurrence modules did not provide evidence of cooperation beyond their constituent pairs, suggesting that the mutational architecture of myeloid neoplasms follows a pairwise grammar. Co-mutation of genes from mutually exclusive pairs primarily reflected higher mutational burden, whereas selected co-occurring pairs retained prognostic associations beyond the individual genes and standard clinical covariates.
Aline Nishimoto, MD: No relevant conflicts of interest to declare.